- Home
- TNXP vs GEVO Comparison
TNXP vs GEVO Comparison
Compare TNXP & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- GEVO
- Stock Information
- Founded
- TNXP 2007
- GEVO 2005
- Country
- TNXP United States
- GEVO United States
- Employees
- TNXP N/A
- GEVO N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- TNXP Health Care
- GEVO Industrials
- Exchange
- TNXP Nasdaq
- GEVO Nasdaq
- Market Cap
- TNXP 207.5M
- GEVO 246.8M
- IPO Year
- TNXP N/A
- GEVO 2011
- Fundamental
- Price
- TNXP $39.78
- GEVO $1.26
- Analyst Decision
- TNXP Strong Buy
- GEVO Buy
- Analyst Count
- TNXP 2
- GEVO 2
- Target Price
- TNXP $585.00
- GEVO $7.58
- AVG Volume (30 Days)
- TNXP 1.3M
- GEVO 3.5M
- Earning Date
- TNXP 05-12-2025
- GEVO 05-13-2025
- Dividend Yield
- TNXP N/A
- GEVO N/A
- EPS Growth
- TNXP N/A
- GEVO N/A
- EPS
- TNXP N/A
- GEVO N/A
- Revenue
- TNXP $10,041,000.00
- GEVO $42,034,000.00
- Revenue This Year
- TNXP $12.17
- GEVO $631.78
- Revenue Next Year
- TNXP $789.15
- GEVO $80.71
- P/E Ratio
- TNXP N/A
- GEVO N/A
- Revenue Growth
- TNXP N/A
- GEVO 145.38
- 52 Week Low
- TNXP $6.76
- GEVO $0.48
- 52 Week High
- TNXP $558.08
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- TNXP 74.56
- GEVO 65.60
- Support Level
- TNXP $25.40
- GEVO $1.00
- Resistance Level
- TNXP $37.84
- GEVO $1.39
- Average True Range (ATR)
- TNXP 4.17
- GEVO 0.08
- MACD
- TNXP 1.75
- GEVO 0.02
- Stochastic Oscillator
- TNXP 87.00
- GEVO 87.22
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.